Have a feature idea you'd love to see implemented?
Let us know!
PGEN Precigen Inc
Price (delayed)
$1.085
Market cap
$317.76M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.55
Enterprise value
$298.79M
Precigen is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases
Highlights
Precigen's debt has decreased by 22% YoY and by 9% from the previous quarter
PGEN's gross margin is up by 9% from the previous quarter
PGEN's gross profit has dropped by 166% year-on-year but it is up by 17% since the previous quarter
PGEN's equity has dropped by 63% year-on-year but it is up by 28% since the previous quarter
PGEN's net income has dropped by 64% year-on-year and by 3.1% since the previous quarter
Precigen's EPS has decreased by 49% YoY
Key stats
What are the main financial stats of PGEN
Market
Valuations
Earnings
Shares outstanding
292.87M
Market cap
$317.76M
Enterprise value
$298.79M
Price to earnings (P/E)
N/A
Price to book (P/B)
4.95
Price to sales (P/S)
75.53
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
75.39
Revenue
$3.96M
Gross profit
-$493,000
Net income
-$139.56M
EBIT
-$141.59M
EBITDA
-$136.11M
Free cash flow
-$84.2M
Per share
Balance sheet
Liquidity
EPS
-$0.55
EPS diluted
-$0.55
Free cash flow per share
-$0.31
Book value per share
$0.22
Revenue per share
$0.01
TBVPS
$0.19
Total assets
$83.47M
Total liabilities
$28.1M
Debt
$5.75M
Equity
$55.38M
Working capital
$13.3M
Debt to equity
0.1
Current ratio
1.63
Quick ratio
1.38
Net debt/EBITDA
0.14
Margins
Efficiency
Dividend
EBITDA margin
-3,434.5%
Gross margin
-12.4%
Net margin
-3,521.7%
Operating margin
-3,551.3%
Return on assets
-126.2%
Return on equity
-177.8%
Return on invested capital
-468%
Return on capital employed
-227.4%
Return on sales
-3,572.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
PGEN stock price
How has the Precigen stock price performed over time
Intraday
1.4%
1 week
-17.8%
1 month
60.67%
1 year
-20.8%
YTD
-3.13%
QTD
-3.13%
Financial performance
How have Precigen's revenue and profit performed over time
Revenue
$3.96M
Gross profit
-$493,000
Operating income
-$140.74M
Net income
-$139.56M
Gross margin
-12.4%
Net margin
-3,521.7%
Precigen's net margin has plunged by 180% YoY and by 14% from the previous quarter
PGEN's operating margin has plunged by 175% YoY and by 11% from the previous quarter
PGEN's gross profit has dropped by 166% year-on-year but it is up by 17% since the previous quarter
PGEN's net income has dropped by 64% year-on-year and by 3.1% since the previous quarter
Growth
What is Precigen's growth rate over time
Valuation
What is Precigen stock price valuation
P/E
N/A
P/B
4.95
P/S
75.53
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
75.39
Precigen's EPS has decreased by 49% YoY
PGEN's equity has dropped by 63% year-on-year but it is up by 28% since the previous quarter
PGEN's P/B is 31% below its 5-year quarterly average of 7.2
PGEN's P/S is 94% below its 5-year quarterly average of 1320.4 but 9% above its last 4 quarters average of 69.0
Precigen's revenue has decreased by 41% YoY and by 10% from the previous quarter
Efficiency
How efficient is Precigen business performance
Precigen's return on sales has shrunk by 187% YoY and by 14% QoQ
The ROIC has plunged by 58% from the previous quarter
PGEN's return on equity is down by 33% since the previous quarter
The ROA has contracted by 28% from the previous quarter
Dividends
What is PGEN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for PGEN.
Financial health
How did Precigen financials performed over time
The company's total assets is 197% higher than its total liabilities
PGEN's current ratio has surged by 58% since the previous quarter but it is down by 42% year-on-year
The company's total assets has shrunk by 56% YoY but it rose by 14% QoQ
Precigen's debt is 90% less than its equity
PGEN's debt to equity has soared by 100% YoY but it is down by 33% from the previous quarter
PGEN's equity has dropped by 63% year-on-year but it is up by 28% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.